Cavendish Global and Global Bio Impact Fund Announce Launch of Cavendish Impact Capital


August 31, 2016

(COOPERSTOWN, NEW YORK) — Cavendish Global, a New York-based community of family offices and impact investors, and Global Bio Impact Fund, a life science investment group headquartered in Southern California, have today announced the formation of Cavendish Impact Capital, an entity that will be composed of a suite of Impact Capital Funds designed to allocate critical capital resources to confront and combat some of humankind’s most pressing global challenges.  The initial fund in the suite, The Cavendish Impact Capital Life Science Fund, will provide vital capital and a path to the marketplace for early-stage health and life science companies whose innovations have the potential to provide a transformational impact on disease prevention, diagnosis or treatment.  

The Cavendish Impact Capital Life Science Fund will be formally announced at the 8th Cavendish Global Health Impact Forum taking place September 18 – 21, 2016 in Phoenix, AZ.

Cavendish Impact Capital, and the targeted funds within it, will be managed by the current leadership of Global Bio Impact Fund under a license agreement with Cavendish Global. Beyond the initial Life Science Fund, the leadership of Cavendish Impact Capital envisions future funds dedicated to provide meaningful impact on challenging issues across a spectrum of sectors. 

Michael Moffat, Chairman of Cavendish Global noted, “The entire Cavendish community is delighted to join forces with the Global Bio team in the launch of a new and unique vehicle for moving paradigm-changing technologies from mind to market. The Cavendish Impact Capital Life Science Fund has the potential to deliver transformational breakthroughs in medicine to those most in need. In working with the Global Bio team over the past few years, we have seen the remarkable synergies between our organizations and the complete alignment of our guiding principles and we look forward to driving meaningful impact on the lives of people around the globe.”

Kirk Wright, Co-Manager of Global Bio added, “The leadership of Global Bio is honored by the faith placed in us by the Cavendish community as we together lead the charge to make a large and lasting global impact by identifying and developing a new generation of brilliant innovators and entrepreneurs who have the potential to address unmet needs across myriad areas of social, medical and environmental challenges. We look forward to collaborating with Cavendish and its wide network of pro-social investors to affect a triple-bottom-line impact and we are excited to be an integral participant in this important effort.”

For more information, please contact: 
Ian Kenyon
Director, Corporate Communications
Cavendish Global